
Otonomy OTIC
Quarterly report 2022-Q3
added 11-10-2022
Otonomy Depreciation & Amortization 2011-2026 | OTIC
Annual Depreciation & Amortization Otonomy
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 856 K | 1.06 M | 1.15 M | 1.19 M | 1.29 M | 708 K | 358 K | 213 K | 257 K | 192 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 192 K | 727 K |
Quarterly Depreciation & Amortization Otonomy
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 668 K | - | 195 K | - | 648 K | - | 221 K | - | 843 K | 569 K | 286 K | - | 854 K | 565 K | 276 K | - | 892 K | 594 K | 295 K | - | 923 K | 592 K | 283 K | - | 496 K | 320 K | 152 K | - | 212 K | 124 K | 60 K | - | 152 K | 100 K | 49 K | - | 194 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 923 K | 49 K | 406 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 326.56 | -2.05 % | $ 42.8 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Aligos Therapeutics
ALGS
|
930 K | $ 7.76 | 4.51 % | $ 76.7 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 21.48 | -0.92 % | $ 1 B | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.45 | 1.32 % | $ 347 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.1 | -4.32 % | $ 5.1 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
154 K | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.41 | -9.12 % | $ 363 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.16 | -1.89 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.22 | -1.46 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.48 | -0.67 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
174 K | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
67 K | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
3.38 M | $ 33.53 | -1.0 % | $ 2.23 B | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
3.92 K | $ 2.66 | -3.34 % | $ 1.18 M |